Squamous cell carcinoma of the lung chemotherapy: Difference between revisions
No edit summary |
|||
Line 5: | Line 5: | ||
==Overview== | ==Overview== | ||
Chemotherapy | Chemotherapy may be required upon histological subtype of squamous cell carcinoma of the lung, molecular testing (presence of genetic mutations), and staging. In most cases, the predominant treatment of choice for squamous cell carcinoma of the lung is neoadjuvant chemotherapy or adjuvant chemotherapy, followed or preceded by surgical resection. Commonly used chemotherapeutic agents, include: cisplatin, erlotinib, paclitaxel, docetaxel, carboplatin, etoposide or vinorelbine.<ref name="lungcancer">Alberti, W; Anderson, G; Bartolucci, A; Bell, D; et al. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. British Medical Journal, International edition311.7010 (Oct 7, 1995): 899 </ref><ref name="wikip"> Moran T, Sequist L. Timing of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Patients With Lung Cancer With EGFR Mutations. J Clin Oncol 2012; 30:3330</ref> | ||
==Chemotherapy== | ==Chemotherapy== | ||
*Initial chemotherapy for patients with squamous cell carcinoma of the lung will depend on molecular testing (presence of genetic | |||
*Combination chemotherapy regimens using | *Initial chemotherapy for patients with squamous cell carcinoma of the lung will depend on molecular testing, the presence of particular genetic mutations, and staging. | ||
*Chemotherapy for patients with squamous cell carcinoma of the lung, is divided into 2 main types: specific-inhibitor therapy (usually indicated with the presence of a genetic mutation) and platinum-based chemotherapy ( usually indicated with the absence of a genetic mutation) | |||
*Combination chemotherapy regimens using platinum-based chemotherapy and specific-inhibitors is the treatment of choice for the management of patients with squamous cell carcinoma of the lung | |||
*Erlotinib is the first-line treatment for patients with squamous cell carcinoma of the lung whose cancer has spread to other parts of the body and that has certain types of epidermal growth factor receptor (EGFR) mutations. | *Erlotinib is the first-line treatment for patients with squamous cell carcinoma of the lung whose cancer has spread to other parts of the body and that has certain types of epidermal growth factor receptor (EGFR) mutations. | ||
*Chemotherapy treatments for squamous cell carcinoma of the lung, include:<ref name="lungcancer">Alberti, W; Anderson, G; Bartolucci, A; Bell, D; et al. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. British Medical Journal, International edition311.7010 (Oct 7, 1995): 899 </ref> | *Chemotherapy treatments for squamous cell carcinoma of the lung, include:<ref name="lungcancer">Alberti, W; Anderson, G; Bartolucci, A; Bell, D; et al. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. British Medical Journal, International edition311.7010 (Oct 7, 1995): 899 </ref> | ||
Line 25: | Line 27: | ||
:*Docetaxel | :*Docetaxel | ||
:*Pemetrexed | :*Pemetrexed | ||
*Platinum-based chemotherapy (cisplatin, carboplatin, etoposide, irinotecan) are the mainstay of squamous cell carcinoma of the lung | *Platinum-based chemotherapy (cisplatin, carboplatin, etoposide, irinotecan) are the mainstay of squamous cell carcinoma of the lung | ||
*Platinum-based chemotherapy consists of four to six cycles | *Platinum-based chemotherapy consists of four to six cycles | ||
* To see more | *Cisplatin is the preferred platinum based agent of choice when the therapy is used with curative intent | ||
* To see more information about mangnagment approach for non-small cell lung cancer click [[Non small cell lung cancer management#Management Approach|here]] | |||
* To see more information about the chemotherapeutic regimens in non-small cell lung cancer click [[Non small cell lung cancer chemotherapy#Chemotherapeutic Regimens|here]] | |||
==Complications== | ==Complications== |
Revision as of 19:33, 7 March 2016
Squamous Cell Carcinoma of the Lung Microchapters |
Differentiating Squamous Cell Carcinoma of the Lung from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Squamous cell carcinoma of the lung chemotherapy On the Web |
American Roentgen Ray Society Images of Squamous cell carcinoma of the lung chemotherapy |
Squamous cell carcinoma of the lung chemotherapy in the news |
Directions to Hospitals Treating Squamous cell carcinoma of the lung |
Risk calculators and risk factors for Squamous cell carcinoma of the lung chemotherapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Shanshan Cen, M.D. [2] Maria Fernanda Villarreal, M.D. [3]
Overview
Chemotherapy may be required upon histological subtype of squamous cell carcinoma of the lung, molecular testing (presence of genetic mutations), and staging. In most cases, the predominant treatment of choice for squamous cell carcinoma of the lung is neoadjuvant chemotherapy or adjuvant chemotherapy, followed or preceded by surgical resection. Commonly used chemotherapeutic agents, include: cisplatin, erlotinib, paclitaxel, docetaxel, carboplatin, etoposide or vinorelbine.[1][2]
Chemotherapy
- Initial chemotherapy for patients with squamous cell carcinoma of the lung will depend on molecular testing, the presence of particular genetic mutations, and staging.
- Chemotherapy for patients with squamous cell carcinoma of the lung, is divided into 2 main types: specific-inhibitor therapy (usually indicated with the presence of a genetic mutation) and platinum-based chemotherapy ( usually indicated with the absence of a genetic mutation)
- Combination chemotherapy regimens using platinum-based chemotherapy and specific-inhibitors is the treatment of choice for the management of patients with squamous cell carcinoma of the lung
- Erlotinib is the first-line treatment for patients with squamous cell carcinoma of the lung whose cancer has spread to other parts of the body and that has certain types of epidermal growth factor receptor (EGFR) mutations.
- Chemotherapy treatments for squamous cell carcinoma of the lung, include:[1]
- Paclitaxel
- Cisplatin
- Erlotinib
- Afatinib
- Gefitinib
- Bevacizumab
- Crizotinib
- Vinorelbine
- Gemcitabine
- Carboplatin
- Etoposide
- Docetaxel
- Pemetrexed
- Platinum-based chemotherapy (cisplatin, carboplatin, etoposide, irinotecan) are the mainstay of squamous cell carcinoma of the lung
- Platinum-based chemotherapy consists of four to six cycles
- Cisplatin is the preferred platinum based agent of choice when the therapy is used with curative intent
- To see more information about mangnagment approach for non-small cell lung cancer click here
- To see more information about the chemotherapeutic regimens in non-small cell lung cancer click here
Complications
- Medical therapy complications for squamous cell carcinoma of the lung will depend on the chemotherapeutic agent.
- Common chemotherapy complications, include:[1]
- Platinum-based chemotherapy, the main dose-limiting side effect of cancer treatment with platinum compounds, include:
- Other chemotherapeutic agent complications, include:
- Side effects symptoms of chemotherapeutic agents, include:
References
- ↑ 1.0 1.1 1.2 Alberti, W; Anderson, G; Bartolucci, A; Bell, D; et al. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. British Medical Journal, International edition311.7010 (Oct 7, 1995): 899
- ↑ Moran T, Sequist L. Timing of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Patients With Lung Cancer With EGFR Mutations. J Clin Oncol 2012; 30:3330